MUC1 and breast carcinoma: Since Wikie et al. demonstrated, for the first time, that anti-MUC1 CAR-T cells generated from the scFv of HMFG2 antibody present in vivo antitumor activity in a breast cancer xenograft [323], a growing number of reports show that this is an active and promising clinical investigation field.